Lesabelimab (LDP) is a monoclonal antibody of the immunoglobulin G1-kappa class, specifically targeting CD274, also known as PD-L1. CD274 functions as an immune checkpoint ligand that inhibits antitumor immune responses by engaging the PDCD1 (PD-1) receptor. This interaction is crucial for modulating immune system activity, particularly in the suppression of T-cell mediated immunity in various cancers. Lesabelimab is designed to disrupt this interaction, thereby enhancing the body's antitumor immune response. This antibody is pivotal for research focused on cancer immunotherapy and the study of immune checkpoint pathways.
Lesabelimab (LDP) is a monoclonal antibody of the immunoglobulin G1-kappa class, specifically targeting CD274, also known as PD-L1. CD274 functions as an immune checkpoint ligand that inhibits antitumor immune responses by engaging the PDCD1 (PD-1) receptor. This interaction is crucial for modulating immune system activity, particularly in the suppression of T-cell mediated immunity in various cancers. Lesabelimab is designed to disrupt this interaction, thereby enhancing the body's antitumor immune response. This antibody is pivotal for research focused on cancer immunotherapy and the study of immune checkpoint pathways.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
